News | May 15, 2015

St. Jude Medical Expands Portfolio of MRI-Compatible Devices to High Voltage in Europe

Company gets approval for one ICD and two pacemakers, with more expected this year

St. Jude Medical, ICD, MRI-conditional, CE mark, Europe, pacemakers

St. Jude Medical's Ellipse ICD

May 15, 2015 — St. Jude Medical Inc. announced CE Mark approval of expanded labeling for its Ellipse implantable cardioverter defibrillator (ICD), in addition to its Durata and Optisure defibrillation leads. The approvals allow existing or future patients with these technologies to undergo magnetic resonance imaging (MRI) scans without compromising device performance. The company also announced that it has received CE Mark approval for its Assurity MRI and Endurity MRI pacemaker device families. The approvals further expand St. Jude Medical’s MRI-conditional device portfolio in Europe.

Designed to offer patients added protection in the event of a life-threatening arrhythmia, the Ellipse device is among the smallest ICDs. The device uses the company’s DynamicTx algorithm, which automatically adjusts shocking configurations for patients in order to ensure the delivery of high-voltage therapy if an electrical short occurs in one part of the system. The Ellipse ICD also utilizes DeFT Response technology, allowing physicians to customize the amount of energy delivered for each individual patient, in addition to low friction coating on the device can. The added coating has been demonstrated in testing to significantly reduce the friction between the device and leads, potentially reducing lead-to-can abrasion, which is one of the most common types of insulation failure in the industry.

“It’s not uncommon for patients with cardiac devices to have an unrelated medical need for an MRI scan over the lifetime of their device,” said Amir Zaidi, M.D., consultant cardiologist at the Manchester Royal Infirmary in Manchester, United Kingdom. “The growing availability of MRI-compatible technologies offered by St. Jude Medical is significant for patients, because it now means they will have access to this important diagnostic tool without compromising their device performance.”

The Assurity MRI and Endurity MRI devices allow early notification of atrial fibrillation-related events and pacing that helps reduce heart failure-related hospitalizations. Both pacemakers are supported by the Patient Care Network (PCN) website for remote patient management.

In the coming months, St. Jude Medical anticipates updated labeling for many of its existing cardiac rhythm management devices, which will allow more patients the ability to safely undergo MRI scans. The company is planning to submit test data in key markets around the world in 2015 for MRI-conditional labeling on additional existing high-voltage products including the Fortify Assura ICD, Quadra Assura CRT-D (cardiac resynchronization therapy defibrillator) and Quartet LV leads.

For more information:

Related Content

Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD) | September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD) | September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD) | July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD) | June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
The Unify ICD is one of the SJM devices in an FDA warning letter
Feature | Implantable Cardioverter Defibrillator (ICD) | April 14, 2017 | Dave Fornell
April 14, 2017 — The U.S. Food and Drug Administration (FDA) sent a warning letter to Abbott/St.
ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation
News | Implantable Cardioverter Defibrillator (ICD) | January 18, 2017
A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-...
ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillator (ICD) | January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
Overlay Init